Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly (NYSE: LLY) has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. AtaiBeckley's lead investigational program, BPL-003, targets treatment-resistant depression, and AtaiBeckley shareholders approved the transaction at a special meeting held prior to closing. Lilly Neuroscience president Carole Ho framed the deal as opening a new treatment paradigm built on rapid-acting therapeutics rather than chronic dosing, expanding Lilly's psychiatry pipeline.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.